Respiratory syncytial virus (RSV)-related respiratory tract infections (including acute bronchitis, bronchiolitis, and pneumonia), all-cause respiratory infections, wheezing episodes.
Conditions
Interventions
Nirsevimab exposed Group:None
Non-exposed Group:None
Sponsors
Guangzhou Women and Children's Medical Center,Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: 1. Term or preterm infants aged 0–1 years during the period from July 1, 2026 to June 30, 2027; 2. Have complete birth and perinatal data; 3. The legal guardian of the study subject agrees to answer the follow-up questionnaire; the study subject and their legal guardian are able to comply with all study procedures; 4. The study subject and their legal guardian are able to comply with all study procedures.
Exclusion criteria
Exclusion criteria: 1. Inability to obtain complete Nirsevimab injection records (for the injection group only); 2. Received Nirsevimab injection during the period from July 2026 to June 2027 or during the follow-up period (for the control group only); 3. Confirmed RSV infection and hospitalization prior to enrollment; 4. Severe congenital malformations; 5. Confirmed RSV infection within 7 days after enrollment; 6. Conditions deemed unsuitable for participation by the attending physician or research personnel.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RSV-related hospitalization rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| ICU admission rate;Length of hospital stay;Growth development (Z-score);All-cause RTI rate;Adverse event rate;Wheezing episodes; | — |
Countries
China
Contacts
Public ContactKeyuan Liu
Guangzhou Women and Children's Medical Center,Guangzhou Medical University
Outcome results
None listed